Reports Q2 revenue $2.58B, consensus $2.64B. “Alcon (ALC) is exiting the second quarter with solid momentum, despite a relatively soft surgical market in the first half of the year,” said David J. Endicott, Alcon’s Chief Executive Officer. “Robust early demand for our recent product launches, including Unity VCS, Voyager, PanOptix Pro, Precision7, Systane Pro PF and Tryptyr, has been encouraging. While it’s still early, these launches position us to accelerate top-line growth, generate cash and deliver long-term value for our shareholders.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALC:
- ALC Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Alcon’s Strategic Acquisition of Staar Surgical: A Buy Rating Amid Growth Prospects and Risk Mitigation
- Snap downgraded, Leidos upgraded: Wall Street’s top analyst calls
- Staar Surgical price target raised to $28 from $20 at Canaccord
- Alcon resumed with an Equal Weight at Wells Fargo